Drug Approval | March 21, 2022
Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
The company plans to launch the product immediately
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
Augnito in association with Japanese company Fujifilm enables voice recognition within their radiology information system platform
The facility will produce 150 million vaccine doses per year
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Subscribe To Our Newsletter & Stay Updated
